EPITARGET is pleased to announce that a new partner – Nanomerics - has joined the EPITARGET Consortium which consists of 18 partners from 9 different European countries and is focused on tackling epilepsy, a disease that affects more than 50 million people world-wide.

Nanomerics will be contributing to the consortium’s therapeutic goals through its Molecular Envelope Technology (MET).  Nanomerics’ MET is useful for the delivery of drugs to the brain and should facilitate the delivery of new epilepsy treatments discovered by the EPITARGET consortium.  The consortium is led by Professor Merab Kokaia of Lund University in Sweden.  Nanomerics’ Chief Executive Officer, Professor Andreas G. Schatzlein says, “I am delighted that the EPITARGET consortium has chosen Nanomerics as one of its key drug delivery partners.  This is a wonderful opportunity to test Nanomerics’ MET in a challenging disease setting and we look forward to working with Merab and his team.”  Professor Merab Kokaia says, “We are really pleased that Nanomerics has agreed to join our consortium and we look forward to working with the company to work on innovative solutions for this condition."

 
Notes for Editors
Nanomerics Ltd. is a private specialty company.  Nanomerics was spun out from UCL and has been operational since 2011.  Nanomerics has an exclusive licence from UCL to the Molecular Envelope Technology, invented by its founders. Nanomerics’ Molecular Envelope Technology comprises a suite of self assembling drug delivery polymers.  Nanomerics is using its Molecular Envelope Technology to develop New Therapeutic Entities.
EPITARGET is a consortium of 18 partners focused on tackling epilepsy and receives funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602102.